Klysmol

Sodium Phosphate Dibasic Heptahydrate / Sodium Dihydrogen Phosphate Monohydrate, the active ingredient in Klysmol, is an osmotic laxative presented as a rectal solution for rectal use. It is employed to cleanse the bowel before diagnostic procedures and to relieve constipation in adult patients.

GNH USA supplies Klysmol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klysmol is an osmotic laxative that works within the gastrointestinal tract to promote bowel evacuation.

Bowel preparation: facilitates colon cleansing before colonoscopy or radiologic imaging. Constipation: stimulates bowel movements to relieve functional constipation in adults.

Klysmol may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Abdominal cramping or discomfort. - Nausea or mild vomiting. - Rectal irritation or burning sensation. - Transient electrolyte disturbances (e.g., mild hyperphosphatemia). - Thirst or mild dehydration. - Flatulence or bloating.

Serious or Rare Side Effects: - Severe electrolyte imbalance such as hyperphosphatemia, hypocalcemia, or hyperkalemia. - Acute renal dysfunction or failure. - Marked dehydration leading to hypotension. - Colonic perforation (very rare). - Severe abdominal pain indicating possible obstruction.

Before using Klysmol, consider the following safety measures.

Assess renal function: avoid in patients with severe renal impairment. Monitor electrolytes: check serum phosphate, calcium, and potassium levels. Use with caution in dehydration: ensure adequate hydration before administration. Avoid in bowel obstruction: contraindicated in mechanical obstruction. Medical supervision required: administration should be overseen by qualified healthcare personnel. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Klysmol can interact with other medicines that affect fluid or electrolyte balance.

Major Interactions (Avoid): - Calcium carbonate or calcium supplements: may exacerbate hyperphosphatemia. - Aluminum‑containing antacids: can reduce phosphate absorption and alter efficacy. - Loop diuretics: increase risk of severe electrolyte disturbances.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may increase risk of renal impairment. - Digoxin: electrolyte shifts can affect cardiac glycoside toxicity.